Researchers at a breast cancer prevention clinic in Manchester, UK, have observed an increased uptake of preventative double mastectomies since May 2013, when Angelina Jolie announced that she had undergone the procedure.
In a Letter to the Editor, published in the open access journal Breast Cancer Research, researchers from the Genesis Prevention Centre Family History clinic report that the number of preventative double mastectomies performed after consultation at the clinic more than doubled from January 2014 to June 2015, with 83 procedures performed during this period, compared to 29 between January 2011 and June 2012.
Although the researchers did not collect information on women’s motivation for undergoing surgery, they speculate that the increase is attributable to the heightened awareness of the procedure since Angelina Jolie publicly announced her decision. Angelina Jolie underwent a preventative double mastectomy after losing her mother to breast cancer and subsequently discovering that she carried a mutation in the BRCA1 gene, which increases the risk of developing breast cancer and ovarian cancer.
At the Genesis Prevention Centre Family History clinic, the number of preventative double mastectomies performed on women with BRCA1/2 mutations rose from 17 in the 18 month period covering January 2011 to June 2012, to 31 in the 18 months from January 2014 onward. The number of procedures performed in high-risk women without BRCA1/2 mutations rose from 12 to 52 over the same period.
Having previously identified an upsurge in referrals to breast cancer clinics immediately after Jolie’s announcement, the authors point out that it takes between 9 and 12 months from initial enquiries to surgery taking place, which is why they hypothesise that they only started to observe increasing numbers of procedures in early 2014. Considering the level of risk identified in the women that underwent a preventative double mastectomy, all the procedures were deemed appropriate. The authors also note that they observed a sustained increase in the number of new referrals to their clinic through 2014, with referrals rising from 201 between January to June 2012, to 388 for the equivalent period in 2014 with a total of 754 referrals in 2014. The authors write that women attending the clinic still mention the effects of Angelina Jolie on their attendance, but these anecdotal reports cannot be formally linked with the uptake in surgery because of their circumstantial nature.
According to Gareth Evans, professor of clinical genetics at Genesis Breast Cancer Prevention, lead author of the letter, “At the Genesis Prevention Centre Family History clinic, we’ve seen a clear increase in the number of women undergoing preventative double mastectomies, starting around nine months after Angelina Jolie’s announcement about her own surgery.”
“While we haven’t analysed women’s motivations for undergoing this type of surgery, the correlation suggests that if the increased uptake of double mastectomies can be attributed to ‘the Angelina effect’, the effect has been prolonged and has resulted in both increased referrals to our clinic, and increased rates of preventative surgery. It would be interesting to see results from other centres in the UK and worldwide to determine whether this effect has been noticed elsewhere.”
This press release refers to a Letter to the Editor of Breast Cancer Research, not a peer-reviewed research paper or article. Letters to the Editor are topical opinion pieces discussing material published in Breast Cancer Research or particular issues of general interest to the readership.
Senior Press Manager
T: +44 (0)20 3192 2243
M: +44 (0) 78 2598 4543
Notes to editor:
Longer term effects of the Angelina Jolie effect: Increased risk reducing mastectomy rates in BRCA carriers and other high-risk women
D. Gareth Evans, Julie Wisely, Tara Clancy, Fiona Lalloo, Mary Wilson, Richard Johnson,
Jonathon Duncan, Lester Barr, Ashu Gandhi and Anthony Howell
Breast Cancer Research 2015
Article available at journal website.
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
2. Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials. www.breast-cancer-research.com
3. Genesis’ mission is to lead ground-breaking research into the prediction and prevention of breast cancer. Its strategy is two-fold; firstly PREDICTION – finding methods of predicting a woman’s personal risk of breast cancer; and secondly PREVENTION – researching ways of lowering women’s risk of developing cancer, in order to prevent the disease.
Genesis’ vision is to create a breast cancer free future for the next generation. Its research will one day bring about a world where breast cancer is preventable and no individual will have to suffer from this terrible disease.
Genesis’ four pillars of research are:-
1. Gene research
2. Early detection and screening
3. Preventative drugs
4. Diet and lifestyle
Genesis Breast Cancer Prevention is the UK’s only charity dedicated entirely to the prediction and prevention of breast cancer. Visit www.genesisuk.org. Media contacts: Steph Cureton or Andrew Shaw at Peppermint Soda. firstname.lastname@example.org Tel: 0161 941 4252
4. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.